Dr. Chen Yaping, Assistant General Manager of Zhongguancun Life Science Park, provides the film crew with an overview of the park.

On October 23, filming crews from TV BRICS and Almaty TV visited the Zhongguancun Life Science Park in Beijing's Changping District to discover the latest innovations in the city's life sciences and biomanufacturing fields.

At the Zhongguancun Life Science Park exhibition hall, the crews gained a comprehensive understanding of the park's development history, functional layout, and key enterprises, while viewing achievements from Beijing's pharmaceutical and health industry cluster.

The exhibition hall, through rich graphics and interactive content, showcased groundbreaking progress in areas such as innovative drugs, medical devices, and synthetic biology. It also highlighted the park's success in promoting the transformation of scientific and technological achievements and fostering an innovation ecosystem.

The Zhongguancun Life Science Park is a key component of the Future Science City in Changping District, Beijing. The park focuses on medical and pharmaceutical technologies, synthetic biology manufacturing, and medical devices, and has attracted more than 2,000 entities in the pharmaceutical and health industries. Centered around the Life Science Park, Changping's biopharmaceutical enterprises have flourished, with 322 national high-tech enterprises, 192 specialized and sophisticated enterprises, and 23 unicorn or potential unicorn companies. In the first half of 2025, large-scale pharmaceutical and health enterprises in Changping District achieved a revenue of 50.32 billion yuan ($7.08 billion), up 9.7 percent year-on-year. Their output value reached 21.83 billion yuan, a 12.2 percent increase, demonstrating strong industrial growth momentum.

A member of the filming crew explores the Chang Development Synthetic Biology Manufacturing Acceleration Center.

Kazakhstan Almaty TV photographer Kyzykbayev Nurbol said, "We learned that with the support of the government and companies, technological progress is very rapid. All the information here is clearly presented. This visit gave me a lot to think about."

Afterward, the filming crew visited the Synthetic Biology Manufacturing Acceleration Center, where they toured the high-throughput strain construction and screening platform. The center was jointly established by Chang Development, Fortune 500 company Danaher Corporation, and the Institute of Process Engineering under the Chinese Academy of Sciences. It serves as a leading innovation service platform integrating incubation, technical services, product transformation, and academic exchange.

At Huahui Health, the crews explored the company's breakthroughs in developing innovative drugs for major diseases such as hepatitis B and D. The company originated from the National Institute of Biological Sciences, Beijing. In 2012, its scientific founder, Dr. Li Wenhui, led a team that discovered the NTCP cell receptor, essential for hepatitis B and D virus infections. Dr. Li received the highest global award in hepatitis B research and treatment in 2021, as well as the Future Science Prize in 2022. The company's independently developed innovative drug, the monoclonal antibody Libevitug (HH-003), has been granted Breakthrough Therapy Designation by drug regulatory authorities in both China and the United States. It is expected to be approved for market release around the end of 2025.

A Kazakhstan photographer films at Huahui Health.